Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of Nitrosporeusines A in drugs for treating rhinitis

A technology for drugs and rhinitis, which is applied in the directions of drug combinations, medical preparations containing active ingredients, and pharmaceutical formulas, and can solve the problems of poor efficacy and ineffectiveness of rhinitis.

Inactive Publication Date: 2014-02-19
JIANGSU KANGQIANG FOOD LIMITED
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, antihistamine drugs such as terfenadine or antiallergic drugs such as tranilast and ketotifen are mainly used in the treatment of rhinitis. These drugs have poor or ineffective effects on chronicity and recurrent rhinitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Nitrosporeusines A in drugs for treating rhinitis
  • Use of Nitrosporeusines A in drugs for treating rhinitis
  • Use of Nitrosporeusines A in drugs for treating rhinitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Embodiment 1: the preparation of compound Nitrosporeusines A tablet involved in the present invention:

[0013] Take 5 grams of compound Nitrosporeusines A, add 195 grams of dextrin, mix well, and make 1000 tablets by conventional tableting.

Embodiment 2

[0014] Embodiment 2: the preparation of compound Nitrosporeusines A capsules involved in the present invention:

[0015] Take 5 grams of compound Nitrosporeusines A, add 195 grams of starch, mix well, pack into capsules and make 1000 capsules.

[0016] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0017] Experimental example 1, the influence of Nitrosporeusines A of the present invention on ovalbumin-induced allergic rhinitis in rats

[0018] Male SD rats, weighing 180-220 g, were intraperitoneally injected with 1 mg of ovalbumin and 10 mg of aluminum hydroxide gel, and then injected once every other day, a total of 7 times. From the 14th day, 10ul of 1mg / ml ovalbumin physiological saline solution was instilled into the nasal cavities of both sides of the rat every day, 7 times in total. Immediately after the last infusion, observe the number of times the rats sneeze and wipe their noses within 30 minutes, and the test drug is orally administered 1 hour before the last infusion of ovalbumin.

[0019] Table 1 Effect of Nitrosporeusines A of the present invention on ovalbumin-induced allergic rhinitis in rats (x±SD)

[0020]

[0021] Compared with the control group, **P<0.01*P<0.05

[0022] It can be seen from Table 1 that Nitrosporeusines A (10, 20mg / kg) significant...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a use of Nitrosporeusines A in preparation of drugs for treating immune-inflammation and especially for treating rhinitis. A contrast test utilizing terfenadine and diclofenac sodium as control groups proves that Nitrosporeusines A has clear effects. Nitrosporeusines A is first disclosed in the invention. Nitrosporeusines A has a novel skeleton type, strong activity of treating rhinitis and substantive distinguishing features, and obviously develops rhinitis prevention and treatment.

Description

technical field [0001] The present invention relates to the new application of compound Nitrosporeusines A, in particular to the application of Nitrosporeusines A in the preparation of medicines for treating rhinitis. Background technique [0002] Rhinitis is a common and frequently-occurring disease in clinical practice. The occurrence of rhinitis is mainly related to allergic reactions and belongs to the category of immune inflammation. At present, antihistamine drugs such as terfenadine or antiallergic drugs such as tranilast and ketotifen are mainly used for the treatment of rhinitis, and these drugs have poor or ineffective effects on chronicity and recurrent rhinitis. Therefore, small molecular compounds with clear components, quality control, safety and high efficiency have potential value in the development of drugs for rhinitis treatment. [0003] The compound Nitrosporeusines A involved in the present invention is published in 2013 (Aigang Yang, et al., Nitrospore...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/403A61P11/02A61P37/08
Inventor 陈斌
Owner JIANGSU KANGQIANG FOOD LIMITED
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com